RNS & Investor News
US launch of LPLDL® with Seed Health
07 June 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the US launch of a product containing its cholesterol and blood pressure reducing strain LPLDL® with Seed Health ("Seed").
OptiBiotix previously announced (RNS: 22 May 2018) that it has entered into a non-exclusive agreement with Seed to produce, promote, market and commercialise products containing LPLDL® in the USA. Seed will market its first product containing LPLDL® under the brand name Daily Synbiotic™ and promote it directly to consumers on its online platform www.seed.com.
Seed was launched on 6 June 2018, with the aim of setting a new standard of scientific rigor and consumer education in the $38 billion global probiotics industry. Daily Synbiotic™, its first product, is targeted at the US probiotic market, one of the largest and fastest growing probiotic markets in the world, with supplements alone accounting for $2.06 billion sales, and a projected 55% growth per annum to $3.3 billion by 2021*.
Seed's team is led by co-founders and co-CEOs, Ara Katz and Raja Dhir, and includes Chief Scientist, Dr. Gregor Reid, a pioneer in the field of probiotics. Seed's Scientific Advisory Board includes some of the world's leading microbiome scientists with expertise in microbiology, immunology, genetics, metabolomics, gastroenterology, paediatrics and women's health.
*Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).
Stephen O'Hara, CEO of OptiBiotix, commented: "We are excited to see the launch of products containing our cholesterol reducing LPLDL® strain in the USA, the world's largest and fastest growing probiotic market. The launch with Seed substantiates the science behind LPLDL® and helps build the LPLDL® brand in the consumer healthcare market around the world. We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL® as the active component in a wide range of products in the USA and around the world."
For further information, please contact:
|OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP
Liam Murray / Jo Turner
|Tel: 020 7213 0880|
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Abigail Wayne (Corporate Broking)
|Tel: 020 7220 0500|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or email@example.com
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.